PEG-GHRF - SeronoAlternative Names: pegylated growth hormone releasing factor; Pegylated growth hormone releasing factor - Serono
Latest Information Update: 26 Jan 2005
At a glance
- Originator Merck Serono
- Mechanism of Action Growth hormone releasing factor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Growth disorders
Most Recent Events
- 22 Dec 2004 Discontinued - Phase-I for Growth disorders in Switzerland (unspecified route)
- 12 Jun 2003 Phase-I clinical trials in Growth disorders in Switzerland (unspecified route)